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A B S T R A C T
Purpose: Anxiety and depression are frequent comorbidities in people with epilepsy (PWE), but possible
gender differences are often neglected. The aim of the present study was to analyze if men and women
with epilepsy differ with regard to anxiety and depressive symptoms and to identify possible predictors.
Methods: Adult consecutive PWE (N = 302; 53% women) completed self-report questionnaires, including
the depression module of the Patient Health Questionnaire (PHQ-9), the anxiety module of the Hospital
Anxiety and Depression Scale (HADS-A) and the subscales ‘‘medication effects’’ and ‘‘seizure worry’’ of
the Patient-weighted Quality of Life in Epilepsy Inventory-31-P (QOLIE-31-P).
Results: There was no gender difference in extent of anxiety (p = .532), which was mainly due to higher
anxiety levels in men compared to the general population. The gender difference in depressive
symptoms was signiﬁcant (p = .009), with female patients being more affected. The most important
predictors for anxiety and depressive symptoms were detrimental effects of medication (QOL
medication effects) and of seizure worry (QOL seizure worry). Moreover, these predictors were more
closely associated with anxiety and depressive symptoms in men.
Conclusion: Future intervention studies could show whether providing more information about the
illness and medication effects may improve anxiety and depression. Our results suggest that such
interventions should be tailored to the different needs of men and women.
 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Depression and anxiety are the most frequent psychiatric
disorders in both people with epilepsy (PWE; prevalence, 20–50%)
[1–4] and the general population (7–20%) [1] and have major
impact on quality of life, morbidity and mortality. In PWE, suicide
is one of the most common causes of death [5,6]. Studies assessing
factors inﬂuencing quality of life in PWE consistently found
depression and anxiety to be far more important than direct
epilepsy-related items such as seizure frequency or antiepileptic
drug (AED) adverse effects [7,8].
The interaction between epilepsy on the one hand and anxiety
and depression on the other is not satisfactorily cleared up yet. The
underlying mechanisms are mostly thought to be bidirectional. For
example, in a population-based study from Iceland, PWE had a
history of depression preceding onset of epilepsy 4–6 times more
often than control subjects [9]. In addition, more than 50% of* Corresponding author. Tel.: +49 30 450 560 038; fax: +49 30 450 560 938.
E-mail address: verena.gaus@charite.de (V. Gaus).
1 These authors contributed equally to this paper.
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1059-1311/ 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights redepressive PWE are present with a family history of psychiatric
illness, affective disorders being the most common condition [4].
However, the opposite pathway is also possible, with epilepsy
leading to more anxiety and depressive symptoms [10]. Some
authors postulate that in PWE psychiatric disorders such as anxiety
and depression represent another clinical manifestation of the
same neurobiological pathogenic mechanism as epilepsy [11].
Another important issue is the role of socioeconomic status, which
was found to be a strong predictor for both depression and anxiety
in the general population [12]. In addition, several AEDs are known
to exhibit unfavorable psychotropic effects and thus may enhance
neuropsychiatric adverse events [13–16]. However, pre-existing
depression can also worsen adverse events of AED. A case-control-
study comparing patients with and without AED treatment for new
onset seizures found depression and female gender to have the
highest predictive value for high adverse event scores [17].
Regarding gender, women in general are considerably more
prone to depression and anxiety than men [18,19]. In PWE, little
systematic evidence exists on gender differences in prevalence of
psychiatric disorders. A Chinese study found anxiety and seizure-
frequency to have a higher inﬂuence on quality of life in men withserved.
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adverse events caused by AED had the highest impact [20]. Similar
data aiming on moderators for anxiety and depression could not be
identiﬁed, which illustrates the striking lack of research in this
ﬁeld.
In summary, the role of anxiety and depressive disorders in
patients with epilepsy is complex and hard to disentangle from
interactions of medical and psychosocial issues. This opens room
for several questions regarding the additional impact of gender
differences on depressive symptoms or anxiety in PWE that have
received surprisingly little attention so far. Hence, the aims of the
study were (1) to assess gender differences in prevalence of anxiety
and depression in PWE, (2) to identify predictors for depression
and anxiety in men and women with epilepsy, and (3) to determine
whether associations between predictors and depressive symp-
toms or anxiety, respectively, were moderated by gender.
2. Methods
2.1. Study population and measurement
Adult PWE were recruited at the outpatient clinic of the
Department of Neurology, Charite´ University Hospital Berlin,
which serves as a tertiary referral center. Patients were consecu-
tively enrolled into this study between February 2011 and March
2012. Inclusion criteria were age 18 years, deﬁnite diagnosis of
epilepsy as deﬁned by the International League against Epilepsy
[21], and the physical, mental, and language ability to complete the
interview adequately. Patients under legal guardianship were
excluded. All patients signed informed consent and the study was
approved by the local ethics committee (EA2/133/10). Data
considered in this analysis were obtained by standardized self-
report questionnaires. Adverse events of AED were assessed by
patients’ perception (‘‘Have you ever/in the last 3 months
experienced side effects of your antiepileptic medication?’’).
Additional clinical data were obtained from medical records of
the epilepsy outpatient clinic. We collected demographic and
clinical information including age at epilepsy onset, age at
interview, sex, body mass index (BMI), epilepsy syndrome and
etiology, epilepsy duration, seizure frequency (occurrence of all
types of seizures in the last 3 months and generalized tonic–clonic
seizures more than once/year as dichotomized variables), adverse
events, and current AED treatment. To take potential psychiatric
side effects possibly inﬂuencing depressive symptoms and anxiety
into account, we performed a subanalysis in patients treated with
AED-monotherapy since side effects can hardly be disentangled in
polytherapy. AED were categorized with respect to potential for
psychiatric side effects based on current literature [13–16]: AED
given in monotherapy with ‘‘potential favorable psychotropic
effect’’ (e.g. mood-stabilizing, anxiolytic) were carbamazepine,
oxcarbazepine, lamotrigine, pregabaline and valproic acid. The
group of AED-monotherapies with ‘‘potential unfavourable psy-
chotropic effect’’ (e.g. affective symptoms) comprised phenobar-
bital, primidone, levetiracetam and topiramate. Levels of education
were categorized into three groups: Low, medium and high
educational level representing up to 9 years, 10 years and 13 years
of schooling, respectively. Quality of life was assessed by means of
the QOLIE-31-P. In the present analysis, we focused on the QOL
subscales ‘‘seizure worry’’ (e.g. ‘‘How fearful are you of having a
seizure during the next month?’’) and ‘‘medication effects’’ (e.g.
‘‘How worried are you, that medications you are taking will be bad
for you if taken for a long time?’’). To assess general anxiety, we
used the anxiety module of the Hospital Anxiety and Depression
Scale HADS-A [22], a standardized questionnaire which has shown
a high validity in evaluating symptoms of anxiety in patients with
chronic diseases [23], and also in PWE [24]. The HADS-A consists ofseven questions, each question offering four possible answers,
which are scored from 0 to 3 points, generating a total score from 0
to 21 points, with higher scores indicating higher levels of anxiety.
To assess the severity of depressive symptoms we used the
depression module of the Patient Health Questionnaire PHQ-9, a
standardized nine-item scale based on DSM-IV-criteria for
diagnosis of depression [25]. Items are endorsed on a 4-point
Likert scale ranging from ‘‘not at all’’ to ‘‘nearly every day’’. The sum
score ranges from 0 to 27 points, with higher scores indicating
higher levels of depression.
2.2. Statistical analysis
Gender differences were compared using the Student’s t-test for
continuous, and Chi-square-tests for categorical variables, respec-
tively. To examine relationships between depression or anxiety
and sociodemographic, psychosocial and clinical variables, Pear-
son’s r was calculated. To examine interactions between different
predictors of anxiety and depression, respectively, and gender,
interaction terms were computed and added to the respective
main effects in the regression equation. Evaluation of assumptions
led to transformation of the PHQ-9 sum score using a square root
transformation to reduce skewness and improve normality. QOL
medication effects and QOL seizure worries were still positively
skewed after the transformation and thus dichotomized using the
median of the original scale as the cut-off (Median QOL medication
effects 42.0; Median QOL seizure worries 73.0).
We used sequential multiple regression analyses to evaluate
the independent inﬂuence of all variables on depression and
anxiety (see [26] for more details). Within these analyses,
sociodemographic variables were entered in the ﬁrst step,
epilepsy-related variables in the second step, and medication-
related variables in the third step. The variables were chosen
relying on previous research and entered the equation according to
theoretical considerations. To avoid overﬁtting, we drew on results
of bivariate analysis and, in addition to sociodemographic
variables, included only variables in respective multiple regression
equation that showed a signiﬁcant correlation with either
depression or anxiety. All regression models were tested for
multicollinearity. Goodness of ﬁt was assessed using Hosmer–
Lemeshow test, and the strength of association was estimated
using Nagelkerke R2. Statistical analysis was performed using SPSS
Statistics 20.0 (SPSS Inc. IL, USA). All tests for statistical signiﬁcance
were two-sided and an alpha level of p  0.05 was considered
signiﬁcant.
3. Results
Of the 319 patients who were asked to participate in our
analysis, 6 declined to take part. Eleven patients were excluded due
to questionable epilepsy diagnosis (N = 6), to incomplete ques-
tionnaires or informed consent forms (N = 4) and previously
unknown legal supervision (N = 1). Finally, the patient sample
(N = 302) consisted of 141 men and 161 women (53%). Men on
average were signiﬁcantly older than women. At onset of epilepsy
women were 8 years younger than men and had more often
generalized epilepsy, whereas men more often had partial epilepsy
and were more frequently treated with AED polytherapy. (Table 1)
Regarding somatic comorbidity, arterial hypertension (N = 56),
orthopedic diseases (N = 40) and thyroid dysfunction (N = 27) were
most frequently named.
Women reported signiﬁcantly more pronounced depressive
symptoms and more QOL seizure worry, whereas levels of anxiety
and QOL medication effects in women equalled those of men
(detailed characteristics are displayed in Table 1).
Table 1
Gender differences in sociodemographic, psychosocial, and epilepsy related variables.
Domain/variable Total (N = 302) Men (N = 141) Women (N = 161) p
Demographic variables
Age, mean  SD 44.5  16.6 49.2  17.3 40.4  14.9 <.001
Without partner, n (%) 96 (32.5) 48 (34.0) 50 (31.1) .580
Children, n (%) 145 (48.0) 66 (46.8) 79 (49.1) .730
Low educational level, n (%) 22 (7.3) 8 (5.7) 14 (8.7) .527
Medium educational level, n (%) 177 (58.6) 82 (58.2) 95 (59.0)
High educational level, n (%) 103 (34.1) 51 (36.2) 52 (32.3)
Somatic comorbidity, n (%) 175 (57.9) 90 (63.8) 85 (52.8) .062
Epilepsy related variables
Age at epilepsy onset (yrs), mean  SD 24.2  18 28.6  20.8 20.4  14.2 <.001
Epilepsy duration (yrs), mean  SD 20.2  16.7 20.4  17.1 20.1  16.5 .850
Generalized epilepsy, n (%) 71 (23.5) 16 (11.3) 55 (34.2) <.001
Partial epilepsy, n (%) 214 (70.9) 120 (85.1) 94 (58.4) <.001
Unclassiﬁed epilepsy syndrome, n (%) 17 (5.6) 5 (3.5) 12 (7.5) .210
Seizures in the last 3 monthsa, n (%) 166 (55.0) 76 (53.9) 90 (55.9) .730
GTCS more than once/yeara, n (%) 87 (31.6) 44 (36.1) 43 (28.1) .192
Seizure worryb, n (%) 141 (47.2) 77 (55.0) 64 (40.3) .015
AED related variables
Polytherapy, n (%) 123 (40.7) 68 (48.2) 55 (34.2) .014
AED psychotropicc (%) 107 (35.4) 42 (29.8) 65 (40.4) .700
Side effects in the last 3 months, n (%) 121 (40.1) 51 (36.2) 70 (43.5) .239
Medication effectsb, n (%) 170 (56.7) 84 (60.0) 86 (56.8) .295
Anxiety and depression
PHQ-9d, mean  SD 6.7  5.2 5.9  5.2 7.4  5.0 .009
HADS-Ae, mean  SD 9.00  2.7 8.9  2.8 9.1  2.6 .532
Note. GTCS = generalized tonic–clonic seizures.
a Dichotomized variable.
b Subscale of QOLIE 31-P = Patient-weighted Quality of Life in Epilepsy, dichotomized variable.
c AED psychotropic = antiepileptic drugs with potential favorable psychotropic effects.
d PHQ-9 = Patient Health Questionnaire—Depression Module.
e HADS-A = Hospital Anxiety and Depression Scale—Anxiety Module.
Table 2
Correlations of clinical variables, depression, and anxiety in men and women with
epilepsy.
Depression Anxiety
Variable Men
(N = 141)
Women
(N = 161)
Men
(N = 141)
Women
(N = 161)
Age .12 .05 .08 .02
Without partner .11 .17* .05 .12
Low education .08 .15+ .16 .12
Generalized epilepsy .06 .23** .07 .27***
Seizures in the last
3 months
.07 .35*** .12 .18*
Seizure worrya .34*** .26*** .40*** .24**
AED Polytherapy .08 .16* .04 .01
AED psychotropicb .12 .29*** .10 .13
Side effects in the
last 3 months
.29*** .13 .08 .09
Medication effectsa .33** .09 .26** .06
+ p < .10.
* p < .05.
** p < .01.
*** p < .001.
a Subscale of QOLIE 31-P: Patient-weighted Quality of Life in Epilepsy.
b AED psychotropic: antiepileptic drugs with potential favorable psychotropic
effects.
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symptoms
In men and women, QOL seizure worry was associated with
depression and anxiety. Other variables were signiﬁcantly correlat-
ed to depression or anxiety speciﬁcally in either men or women. In
men, the experience of adverse effects in the last 3 months was
associated with depression, whereas QOL medication effects (i.e. the
fear of sequelae of long term AED therapy), were associated with
depression and anxiety. In women, a diagnosis of partial epilepsy
and occurrence of seizures in the last 3 months showed a positive
correlation with depression and anxiety, whereas generalized
epilepsy was conversely correlated with these variables. In female
patients, antiepileptic polytherapy and AED with potential unfavor-
able psychotropic effects were also associated with depressive
symptoms. PWE treated with AED with potentially favorable
psychotropic effects showed fewer depressive symptoms (Table 2).
To examine the unique contribution of epilepsy- and medica-
tion-related variables in the explanation of depressive symptoms,
a sequential multiple regression analysis was performed (Table 3).
DR2 refers to the amount of variance of depression explained by
the respective variables entered in each step into the regression
model. Neither in men nor in women did sociodemographics
signiﬁcantly explain variance in depression. In men, R2 was
signiﬁcantly different from zero after entry of epilepsy-related
variables in the second step (DR2 = .10) and from medication-
related variables in the third step (DR2 = .13). In this multiple
regression, QOL seizure worry, adverse effects in the last 3 months,
and QOL medication effects remained signiﬁcant predictors. In
women, seizures in the last 3 months, QOL seizure worry, and AED
with unfavorable psychotropic effects were independently associ-
ated with depressive symptoms. However, only epilepsy-related
variables led to a signiﬁcant change in R2 (DR2 = .17).Results from the sequential multiple regression analyses on
anxiety are shown in Table 4. In men, only epilepsy-related
variables led to a signiﬁcant change in R2 (DR2 = .17). The size of the
relationships suggests that QOL seizure worry was the most
important predictor, explaining almost 17% of the variability of
anxiety in men. In addition to QOL seizure worry, age and QOL
medication effects were independently associated with higher
levels of anxiety. However, addition of QOL medication effects did
not reliably improve R2. In women, generalized epilepsy and QOL
Table 3
Sequential regression analysis of depressive symptomsa on sociodemographic, epilepsy related, and medication related variables.
Men Women
B S.E. b DR2 (adj. R2) B S.E. b DR2 (adj. R2)
Step 1—sociodemographics .03 .05
Age .00 .01 .02 .01 .01 .04
With partner .19 .20 .08 .28 .15 .13
Low education .45 .41 .09 .18 .25 .05
Step 2—epilepsy related .10** .17***
Generalized epilepsy .09 .30 .02 .29 .16 .14
Seizures in the last 3 months .00 .20 .00 .54 .16 .27***
Seizure worriesb .63 .20 .26*** .40 .16 .19**
Step 3—medication related .13*** .05
Polytherapy .27 .25 .11 .28 .19 .13
AED psychotropicc .31 .26 .12 .48 .18 .24**
Side effects in the last 3 months .63 .20 .25*** .17 .16 .08
Medication effectsb .52 .20 .21** .16 .16 .08
R2 (adjusted R2) .26 (20) .27 (22)
** p < .01.
*** p < .001.
a Square root transformed.
b Subscale of QOLIE 31-P: Patient-weighted Quality of Life in Epilepsy.
c AED psychotropic = antiepileptic drugs with potential favorable psychotropic effects.
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sequential regression analysis, with epilepsy-related variables
leading to a small, but signiﬁcant change of R2 (DR2 = .11).
To assess whether the strength of associations between
independent and dependent variables differed among men and
women, we conducted additional regression analyses with the
whole sample including interaction effects. In these multiple
regression analyses, the interaction between gender and QOL
medication effects reached signiﬁcance with respect to both anxiety
(b = .49; p = .008) and depressive symptoms (b = .58; p = .001) with
stronger associations for men. In addition, the interaction between
QOL seizure worries and gender with anxiety as dependent variable
was also signiﬁcant (b = .36; p = .043). Again, QOL seizure worries
and anxiety were more closely associated in men.
4. Discussion
The main aim of this study was to assess possible gender
differences in anxiety and depression in PWE. We have identiﬁedTable 4
Sequential regression analysis of anxiety on sociodemographic, epilepsy related, and m
Men 
B S.E. b 
Step 1—sociodemographics 
Age .03 .01 .20*
With partner .00 .48 .00 
Low education .57 .97 .05 
Step 2—epilepsy related 
Generalized epilepsy .33 .69 .04 
Seizures in the last 3 months .24 .47 .04 
Seizure worriesa 2.11 .48 .38***
Step 3—medication related 
Polytherapy .73 .60 .13 
AED psychotropicb .32 .62 .05 
Side effects in the last 3 months .40 .46 .07 
Medication effectsa 1.09 .47 .19*
R2
* p < .05.
** p < .01.
*** p < .001.
a Subscale of QOLIE 31-P: Patient-weighted Quality of Life in Epilepsy.
b AED psychotropic: antiepileptic drugs with potential favorable psychotropic effectthree key ﬁndings. First, men in our population do not exhibit
lower levels in anxiety than women, as opposed to the general
population. On the other hand, the expected gender difference in
depression, with higher depression scores in women, is actually
also seen in PWE. Second, the most important predictors for
anxiety and depression are QOL medication effects (worries about
AED adverse effects and perceived adverse effects) and QOL seizure
worry (worries about possible seizures) and not the actual health
status. Third, in men QOL medication effects and QOL seizure
worry are stronger predictors for anxiety than in women.
4.1. Anxiety in men and women with epilepsy
High levels of anxiety in PWE without a gender difference is
striking because in the general population men and women show a
pronounced and consistent difference in anxiety, with women
experiencing higher anxiety levels than men [27]. Commonly, this
gender difference is even more pronounced in patients with other
chronic medical conditions such as coronary heart disease [28,29].edication related variables.
Women
DR2 (adj. R2) B S.E. b DR2 (adj. R2)
.02 .03
.01 .01 .04
.63 .43 .11
.63 .70 .07
.17*** .11***
1.17 .44 .21**
.64 .44 .12
0.95 .44 .18*
.05 .03
1.02 .54 .18
.67 .50 .13
.57 .43 .11
.36 .45 .07
.24 (.18) .17 (.11)
s.
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line with previous studies [20,30], but so far it has not gained much
attention. Yet the lack of difference in this context is such a
discrepancy that it requires explanation. In our study, the reason
for the unusual ﬁnding is clearly attributable to higher anxiety
levels in men compared to the healthy men in the norm
population. Even though women with epilepsy also report higher
anxiety levels than women of the norm sample, the levels of men in
our sample are so much higher that they equal those of women
(HADS norm sample N = 4410 [31]; Supplemental Fig. 1).
Multiple regression analysis indicates the most important
predictors for anxiety in the current cohort. In men, QOL seizure
worry and QOL medication effects clearly emerge as the most
important predictors after controlling for epilepsy characteristics.
In women, no medication-related variable is independently related
to anxiety. As in men, QOL seizure worries are associated with
anxiety, but in women this association is much weaker. Altogether,
QOL seizure worry and QOL medication explain about 18% of
variance in men, but only 11% in women. This leads to the
assumption that seizure worries and the perception of medication
effects may be more stressful for men than for women. Even
though gender stereotypes have weakened over the last 20 years,
social roles of men and women still differ [32]. Men still seem to be
under more pressure to have a successful career and to be able to
support a family. Therefore, a severe chronic disease like epilepsy
which may be associated with a looming loss of control may still be
even more stressful for men than for women (cf. [20]). In addition,
it is still socially less accepted for men to express feelings of
uncertainty and anxiety, which makes it more difﬁcult for
physicians and relatives to bring up this issue and to help male
patients to deal with their emotions. A third point which may
contribute to higher anxiety levels in men is the fact that due to the
age-dependent distribution of epilepsy syndromes on average men
are 8 years older at the onset of epilepsy than their female
counterparts. Therefore, at the onset men may be more advanced
in their psychosocial development, but on the contrary they may
also be less ﬂexible in developing adaptive coping strategies. Thus,
men may need more information on medication and on epilepsy.
One clinical implication of enhanced anxiety in male PWE may be
tailored AED treatment omitting substances that have the
potential to induce or enhance anxiety (for review, see [33]).
4.2. Depressive symptoms in men and women with epilepsy
Our results indicate that women with epilepsy report more
depressive symptoms than men, a ﬁnding which is also present in
the general population (PHQ norm sample N = 2066, [34];
Supplemental Fig. 2). Similar to anxiety, QOL seizure worries
were independently predictive of depression in both genders. In
men, depression was also independently associated to medication
effects, in particular to worries about medication effects. In both
genders, the explanation of variance in depression was not due to
sociodemographic factors, but almost exclusively due to epilepsy-
and medication-related variables. In clinical practise, it can be very
difﬁcult to deﬁne the main reason for psychiatric disorders in PWE,
because many factors may have a signiﬁcant impact. However, this
study shows some interesting associations, and as most of the
detected predictors for depression seem accessible to modiﬁcation,
the ﬁndings provide further support for the importance of
educational interventions. In order to increase quality of life and
to prevent suicide, which is still one of the main causes of death in
PWE [35], screening for depression and searching for possible
causes should become part of the clinical routine. This is still not
the case as almost 80% of US neurologists do not routinely screen
for depressive symptoms in their epilepsy outpatients [36]. Of
course, the association between depression and medication effectsis likely to be bidirectional: medication effects and worries about
medication effects may enhance depressive symptoms, which –
vice versa – may well also reinforce the perception of adverse
effects of antiepileptic drugs [37].
4.3. Limitations
There are possible limitations to this study which should be taken
into account when interpreting its results. First, the PHQ-9 is a brief
screening instrument to assess severity of depressive symptoms. It
does not replace the need to make a formal clinical diagnosis of
depression. However, given the strong evidence for its high
sensitivity and speciﬁcity, this instrument seems appropriate for
investigating epidemiological questions. Another limitation refers to
the norm samples for depression and anxiety that are not
differentiated by age and education. This might inﬂuence the
comparability. However, many studies have shown that the effect
of gender in this context is usually greater than the effect of age and
education. Second, the cross-sectional design does not allow for
causal interpretations. Further studies are needed to clarify the
direction of the inﬂuence. Third, all patients were recruited at a single
center in a specialized outpatient clinic hampering generalizability of
our ﬁndings. It is possible that difﬁcult-to-treat epilepsies are
overrepresented and that the studysample reﬂectsa slightly selected,
less healthy population. Fourth, some basic demographic and
epilepsy variables differed between men and women well reﬂecting
the everyday clinical setting. However, we carefully controlled for
these differences, which allows for reliable interpretation of the
current ﬁndings. Finally, we are well aware that data on favorable and
unfavorable neuropsychiatric medication effects are not homoge-
neous, with new evidence still coming up. Nevertheless, we consider
the potential inﬂuence of AED on neuropsychiatric symptoms a very
important issue. In spite of some inconsistencies, we therefore
included this aspect in patients treated with AED-monotherapy.
5. Conclusion
Men with epilepsy exhibit markedly higher levels of anxiety
than healthy male controls eventually equalling those of female
epilepsy patients. Particularly in men, anxiety and depression are
signiﬁcantly associated with seizure and medication worries.
Further studies are needed to show whether comprehensive
information about antiepileptic drugs and epilepsy itself may
improve quality of life and thereby yield a positive impact on
anxiety and depression. Our results suggest that such interven-
tions should be tailored to the different needs of men and women.
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